Therapeutic protein kinase inhibitors
- PMID: 19011754
- PMCID: PMC11131522
- DOI: 10.1007/s00018-008-8539-7
Therapeutic protein kinase inhibitors
Abstract
Protein kinase inhibitors represent an important and still emerging class of targeted therapeutic agents. Drug discovery and development strategies have explored numerous approaches to target the inhibition of protein kinase signaling. This review will highlight some of the strategies that have led to the successful clinical development of therapeutic protein kinase inhibitors, particularly as anticancer drugs. Some notable advances have been made in the development of novel protein and oligonucleotide-based biologics that target growth factor or receptor tyrosine kinases. Also, advances have been made in the rational design of small-molecule inhibitors that target unique kinase conformational forms and binding sites, and have specific kinase selectivity profiles. A review will also be given of some of the potential clinical toxicities and adverse side-effects associated with these kinase-targeted drugs. Therapeutic protein kinase inhibitors have been highly beneficial to cancer patients and offer the promise of future therapies for other diseases as well.
Similar articles
-
Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003. Epub 2018 Mar 21. Biochim Biophys Acta Rev Cancer. 2018. PMID: 29574128 Review.
-
Role of tyrosine kinase inhibitors in cancer therapy.J Pharmacol Exp Ther. 2005 Dec;315(3):971-9. doi: 10.1124/jpet.105.084145. Epub 2005 Jul 7. J Pharmacol Exp Ther. 2005. PMID: 16002463 Review.
-
Targeting multiple kinase pathways: a change in paradigm.Clin Cancer Res. 2010 Apr 1;16(7):1973-8. doi: 10.1158/1078-0432.CCR-09-3182. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215532 Free PMC article. Review.
-
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. Mol Cancer Ther. 2006. PMID: 16891463
-
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.Semin Oncol. 2006 Aug;33(4):407-20. doi: 10.1053/j.seminoncol.2006.04.005. Semin Oncol. 2006. PMID: 16890796 Review.
Cited by
-
Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.Oncotarget. 2012 Oct;3(10):1169-81. doi: 10.18632/oncotarget.600. Oncotarget. 2012. PMID: 23045411 Free PMC article.
-
Does activation of the FcgammaRIIa play a role in the pathogenesis of the acute lung injury/acute respiratory distress syndrome?Clin Sci (Lond). 2010 Jan 26;118(8):519-26. doi: 10.1042/CS20090422. Clin Sci (Lond). 2010. PMID: 20088831 Free PMC article.
-
Viewing serine/threonine protein phosphatases through the eyes of drug designers.FEBS J. 2013 Oct;280(19):4739-60. doi: 10.1111/febs.12481. Epub 2013 Sep 5. FEBS J. 2013. PMID: 23937612 Free PMC article. Review.
-
Screening and identification of small molecule inhibitors of ErbB2-induced invasion.Mol Oncol. 2014 Dec;8(8):1703-18. doi: 10.1016/j.molonc.2014.07.004. Epub 2014 Jul 12. Mol Oncol. 2014. PMID: 25070180 Free PMC article.
-
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.Cancers (Basel). 2021 Jan 7;13(2):184. doi: 10.3390/cancers13020184. Cancers (Basel). 2021. PMID: 33430292 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
